Coagulation disorders encompass a spectrum of inherited and acquired conditions that disrupt the delicate balance of haemostasis, leading to either excessive bleeding or thrombosis. Among these, ...
Researchers at McMaster University have made a discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with ...
Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders. Learn ...
Aortic aneurysms pose a unique haemostatic challenge, frequently giving rise to a consumptive coagulopathy characterised by simultaneous activation of clotting and fibrinolytic pathways. The presence ...
Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today ...
Weill Cornell Medicine investigators have revealed the detailed workings of a cell membrane protein that has essential roles in all animals. The discovery could lead to new therapeutic strategies for ...
Researchers at McMaster University have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite ...
NovoSeven RT is a prescription drug used to treat certain blood clotting disorders, including hemophilia. The drug is given as an intravenous (IV) infusion, which is an injection into a vein over a ...
To help diagnose von Willebrand disease or other bleeding disorders, a doctor will request various blood tests. These tests will measure the presence and activity of certain substances in the blood.
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation ...
New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; ...
Researchers at McMaster University have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite ...